Last reviewed · How we verify

Infection by Strongyloides — Treatment Landscape & Competitive Intelligence

Infection by Strongyloides (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Infection by Strongyloides, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Stromectol ivermectin Merck & Co. Antiparasitic [EPC] Adenosine receptor A3, Multidrug resistance protein 1, Neuronal acetylcholine receptor subunit alpha-7

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Infection by Strongyloides
  2. Merck & Co. · 1 drug in Infection by Strongyloides

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Infection by Strongyloides:

Cite this brief

Drug Landscape (2026). Infection by Strongyloides — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infection-by-strongyloides. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing